May. 6, 2012
On May 7, 2012, Enzon Pharmaceuticals and Zhejiang Hisun Pharmaceuticals announced a long-term strategic research, development and licensing collaboration. The agreement provides for the research and development of therapeutics using Enzon's customized PEGylation linker technology. The agreement also licenses Hisun the development and commercialization rights for Enzon's PEG-SN38 (EZN-2208), a novel, Phase II PEGylated version of SN38, in the territory of China.